FDA approves Teva's treatment for Huntington disease: 3 things to know

The Food and Drug Administration on Monday approved Teva Pharmaceuticals' new treatment for Huntington's disease, a fatal degenerative disorder.

Here are three things to know.

1. Austedo is intended to treat chorea — an involuntary movement disorder — associated with Huntington's. Ninety percent of patients with the disease experience chorea.

2. The drug represents the second FDA-approved treatment for Huntington's.

3. Teva said the drug will be available in the next three weeks.

More articles on supply chain:

11 drugs on FDA's new safety alert list
How SSM Health's pharmacy concierge program helps patients manage high drug costs
Sanofi agrees to pay $20M for overcharging VA for vaccines: 4 things to know

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Learning Opportunities

Featured Whitepapers

Featured Webinars